# A Study of HDM2024 in Participants With Advanced Solid Tumors

> **NCT07539285** · PHASE1 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 63 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** HDM2024

## Key facts

- **NCT ID:** NCT07539285
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2027-04-15
- **Final completion:** 2028-12-28
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07539285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07539285, "A Study of HDM2024 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07539285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*